Histamine type 2-receptor antagonists and cancer immunotherapy.
Smith
T
T
Division of Hematology/Oncology, Massey Cancer Center, Medical College of Virginia, Richmond 23298-0037.
D002927:Cimetidine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015738:Famotidine / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011899:Ranitidine / Q000627:therapeutic use; D013491:Suppressor Factors, Immunologic
D006635:Histamine H2 Antagonists; D013491:Suppressor Factors, Immunologic; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine